Skip to main content
. 2023 Jul 22;16:78. doi: 10.1186/s13045-023-01483-9

Fig. 1.

Fig. 1

Cell-surface antigens as potential therapeutic targets for NKTCL. mAb: monoclonal antibody, ADC: antibody–drug conjugate, BiTE: bispecific T cell antigen, CAR: chimeric antigen receptor, LMP: latent membrane protein, PD-1: programmed cell death protein 1, PD-L1: programmed cell death ligand 1